Arrowhead Pharmaceuticals, Inc. (LON: 0HI3)

Arrowhead Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Net Income	-599.49	-599.49	-205.28	-176.06	-140.85	-84.55
Depreciation & Amortization	18.6	18.6	12.49	10.42	8.27	5.94
Loss (Gain) From Sale of Investments	0.08	0.08	-	4.43	-1.71	-0.02
Stock-Based Compensation	73.97	73.97	78.13	120.89	76.67	43.38
Other Operating Activities	18.91	18.91	12.31	2.48	0.27	0.53
Change in Accounts Receivable	-	-	1.41	8.85	-9.41	-0.18
Change in Accounts Payable	-5.54	-5.54	33	-6.59	2.63	-0.82
Change in Unearned Revenue	-0.87	-0.87	-129.18	-112.5	223.26	-63.51
Change in Other Net Operating Assets	31.49	31.49	43.23	11.95	12.19	3.44
Operating Cash Flow	-462.85	-462.85	-153.89	-136.13	171.31	-95.8
Capital Expenditures	-141.47	-141.47	-176.74	-52.78	-23.57	-11.95
Investment in Securities	-278.6	-278.6	80.58	47.36	-118.11	-228.83
Investing Cash Flow	-420.07	-420.07	-96.16	-5.42	-141.68	-240.78
Long-Term Debt Issued	392	392	-	-	-	-
Net Debt Issued (Repaid)	392	392	-	-	-	-
Issuance of Common Stock	431.65	431.65	3.05	5.19	11.31	257.95
Other Financing Activities	46.87	46.87	250	60	-	-
Financing Cash Flow	870.52	870.52	253.05	65.19	11.31	257.95
Foreign Exchange Rate Adjustments	4.2	4.2	-0.12	-0.07	-0.09	0.41
Net Cash Flow	-8.21	-8.21	2.89	-76.43	40.85	-78.22
Free Cash Flow	-604.32	-604.32	-330.63	-188.91	147.75	-107.75
Free Cash Flow Margin	-17018.30%	-17018.30%	-137.34%	-77.67%	106.84%	-122.46%
Free Cash Flow Per Share	-5.05	-5.05	-3.10	-1.79	1.42	-1.07
Cash Income Tax Paid	3.74	3.74	-	0	0	-0.1
Levered Free Cash Flow	-440.13	-440.13	-251.42	-60.64	63	-78.67
Unlevered Free Cash Flow	-419.91	-419.91	-239.96	-60.64	63	-78.67
Change in Net Working Capital	-4.67	-4.67	25.72	27.61	-94.77	57.82

Source: S&P Capital IQ. Standard template. Financial Sources.